Key result
Heart failure patients show ~22 percentage points higher GLP-1 agonist eligibility vs. controls, driven by obesity.
Why the study?
Data are limited regarding the burden of obesity among heart failure patients in real-world samples, despite the promise of GLP-1 agonists.
Cross-Sectional (n=2,373)
No
A large majority of patients hospitalized with heart failure at an urban safety net hospital (particularly those with HFpEF) are eligible for GLP-1 agonist therapy, highlighting a major logistical and public health challenge for equitable implementation.
Answers are grounded in this paper and cite their sources.
High GLP-1 eligibility in HF admissions warrants targeted implementation research; leaves open equitable access and outcome benefits in diverse populations.
Introduction: Novel obesity medications (glucagon-like peptide-1 [GLP-1] agonists) show promise for treatment of patients with obesity and heart failure (HF), especially with preserved ejection fraction (HFpEF). However, data are limited regarding the burden of obesity among HF patients in real-world samples. Methods: We conducted a retrospective electronic medical record-based query of HF patients at a single urban safety net hospital system. Results: In 1373 patients (mean age 67 ± 14 years, 59 % women) admitted for acute HF (563 [41 %] with HFpEF, 649 [47 %] with reduced ejection fraction, and 161 [12 %] without ejection fraction assessment), up to 64 % met eligibility criteria GLP-1 agonists compared with 42 % of control patients admitted for non-HF diagnoses. This was primarily driven by higher obesity prevalence. Discussion: The majority of HF patients at an urban safety net hospital are eligible for GLP-1 agonist medications; allocation of these medications to a large patient population represents a major public health challenge.
No takes yet. Share an insight, caveat, or question.
Yee et al. (2025) conducted a cross-sectional in Heart Failure (n=2,373). Heart failure diagnosis vs. Non-heart failure admission (controls) was evaluated on Eligibility for GLP-1 agonist therapy (based on diabetes, BMI ≥30 kg/m2, or BMI ≥27 kg/m2 with a weight-related comorbidity) (p=<0.001). Up to 64% of heart failure patients met eligibility criteria for GLP-1 agonist therapy compared with 42% of control patients admitted for non-heart failure diagnoses, primarily driven by a higher obesity prevalence.
Synapse has enriched 10 related papers. Consider them for comparative context: